Abatacept - CISMeF

Preferred Label : Abatacept;

MeSH definition : A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS.;

CISMeF synonym : 188667, BMS;

MeSH hyponym : BMS224818; LEA29Y; BELATACEPT; BMS 188667; orencia; nulojix; CTLA-4-Ig; BMS-224818; BMS 224818; BMS-188667; BMS188667; Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin; Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin; CTLA4-Ig; CTLA4-Ig Immunoconjugate; CTLA4 Ig Immunoconjugate; Immunoconjugate, CTLA4-Ig; CTLA4-Fc;

MeSH Related Number : 332348-12-6;

Wikipedia link : https://en.wikipedia.org/wiki/Abatacept;

Is substance : O;

UNII : 7D0YB67S97;

Details

Origin ID

D000069594;

UMLS CUI

C1619966;

ATC code(s)
- abatacept [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- ultrastructure [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Abatacept [NCIt concept]
- Abatacept (substance) [SNOMED CT concept]
Currated CISMeF NLP mapping
- Abatacept [ICD-11 Extension code]
- Abatacept [SMS substance]
- Abatacept [Anticorps monoclonal]
- abatacept [International Nonproprietary Name]
Exact mapping(s) to DCI
- abatacept [International Nonproprietary Name]
Pharmacological action(s)
- Immune Checkpoint Inhibitors [MeSH Descriptor]
- antirheumatic agents [MeSH Descriptor]
- immunosuppressive agents [MeSH Descriptor]
Record concept(s)
- BELATACEPT [MeSH concept]
- BMS 188667 [MeSH concept]
- BMS224818 [MeSH concept]
- CTLA-4-Ig [MeSH concept]
- LEA29Y [MeSH concept]
- abatacept [MeSH concept]
- nulojix [MeSH concept]
- orencia [MeSH concept]
See also
- CTLA-4 antigen [MeSH Descriptor]
See also inter- (CISMeF)
- Product containing abatacept (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Abatacept [NCIt concept]
- Abatacept (substance) [SNOMED CT concept]
- Product containing abatacept (medicinal product) [SNOMED CT concept]
- abatacept [ATC Code]
- abatacept [International Nonproprietary Name]
Validated automatic mappings to BTNT
- Belatacept [SMS substance]
- abatacept [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients